Prostate cancer · 12 regimens
Cost vs Efficacy · 3 points
| Regimen | Biomarker | Cost/cycle ↓ | Cycle | PFS ↕ | OS ↕ | Est. cycles | Course cost ↕ | Evidence |
|---|---|---|---|---|---|---|---|---|
Cabozantinib monotherapy Variant #01 | — | R 151 638 | 28d | — | 11.0 mo | 2 | R 303 276 PFS proxy | 1 |
Cabazitaxel and Prednisone Variant #01 | — | R 13 228 | 21d | — | 14.5 mo | 11 | R 145 503 PFS proxy | 7 |
Cabazitaxel and Prednisolone Variant #01 | — | R 13 227 | 21d | — | — | ~20 | ~R 264 532 indirect | — |
Docetaxel, Enzalutamide, Prednisolone Variant #01 | — | R 13 180 | 21d | 9.5 mo | — | 11 | R 144 975 PFS proxy | 1 |
Mitoxantrone and Hydrocortisone Variant #01 | — | R 6 415 | 21d | — | 12.3 mo | 2 | R 12 830 PFS proxy | — |
Carboplatin and Docetaxel (DCb) Variant #06 | — | R 5 501 | 21d | ~4.7 mo | ~22.3 mo | ~6 | ~R 33 004 PFS proxy · indirect | 4 |
Carboplatin, Docetaxel, Prednisone Variant #01 | — | R 5 244 | 28d | — | — | ~2 | ~R 10 488 indirect | — |
Docetaxel and Prednisone Variant #01 | — | R 4 886 | 42d | — | 21.2 mo | 5 | R 24 429 PFS proxy | 13 |
Mitoxantrone and Prednisone Variant #01 | — | R 4 413 | 21d | — | 14.2 mo | 10 | R 44 134 PFS proxy | 2 |
Docetaxel and Estramustine Variant #01 Partial | — | R 1 948 | 21d | — | 17.5 mo | 2 | R 3 895 PFS proxy | 1 |
Docetaxel and Prednisolone Variant #01 | — | R 1 630 | 14d | 8.3 mo | 19.1 mo | 2 | R 3 261 PFS proxy | 3 |
Carboplatin and Paclitaxel (CP) Variant #02 | — | R 1 025 | 21d | — | ~13.8 mo | ~18 | ~R 18 445 PFS proxy · indirect | — |
12 of 12 regimens shown